Hybridopa Shows Motor, Nonmotor Gains in Phase 2a Parkinson Disease Trial

May 21, 2026

More like this

Beyond the Pill: Remepy's Hybrid Drug Shows It Can Remodel Brain Networks

Brief Glance

Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson's Patients Associated with Improved Clinical Outcome

Press Release

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Drug Discovery & Development